PTHS · Pelthos Therapeutics Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 2, 2025; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -13.74M | Six Months Ended June 30, 2026 | — |
| Unique prescribers of Zelsuvmi | 4,571 | Q2 2026 | — |
|
|
|||
| Unique prescribers of Zelsuvmi (cumulative since launch) | 7,414 | As of June 30, 2026 | — |
| Zelsuvmi net product revenue quarter-over-quarter increase | 45% | Q2 2026 | — |
| Zelsuvmi units dispensed (cumulative since launch) | 29,126 | As of June 30, 2026 | — |
| Zelsuvmi units dispensed by unique prescribers | 11,925 | Q2 2026 | — |
| Zelsuvmi units dispensed quarter-over-quarter increase | 48% | Q2 2026 | — |
| territory managers engaged in commercialization efforts related to ZELSUVMI | 64 | first quarter of 2026 | — |
| ZELSUVMI units dispensed | 7,884 | first quarter of 2026 | — |
|
|
|||
| ZELSUVMI units prescribed | 7,884 | first quarter of 2026 | — |
| sales representatives | 64 | fiscal year 2025 | — |
| ZELSUVMI unique prescribers | 2,712 | fiscal year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTHS
this stock
Pelthos Therapeutics Inc.
|
$105.28M | -11.3% | — | — | 1.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 2, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTHS | -3.0% | +1.9% | +24.3% | -4.1% | -11.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.4% | -2.6% | +10.5% | -8.0% | -25.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.